Isoform-selective inhibition of JAK kinases is of key interest in drug discovery. A novel pocket in the JAK pseudokinase domain was targeted by an allosteric covalent inhibitor, leading to specific JAK1 inhibition and providing a deeper understanding of cytokine signaling.
This is a preview of subscription content, log in via an institution to check access.
References
Schwartz, D. M. et al. Nat. Rev. Drug Discov. 17, 78 (2017).
Spinelli, F. R., Meylan, F., O’Shea, J. J. & Gadina, M. Eur. J. Immunol. 51, 1615–1627 (2021).
Kavanagh, M. E. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-022-01098-0 (2022).
Hammarén, H. M., Virtanen, A. T., Raivola, J. & Silvennoinen, O. Cytokine 118, 48–63 (2019).
Vinogradova, E. V. et al. Cell 182, 1009–1026.e29 (2020).
Wylie, A. A. et al. Nature 543, 733–737 (2017).
Glassman, C. R. et al. Science 376, 163–169 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
O.S. holds intellectual property rights to JAK kinases, is a scientific advisory board member and co-founder of Ajax Therapeutics and has received speaking honoraria from Pfizer and Abbvie.
Rights and permissions
About this article
Cite this article
Silvennoinen, O., Haikarainen, T. & Virtanen, A. Aiming for the pocket. Nat Chem Biol 18, 1296–1297 (2022). https://doi.org/10.1038/s41589-022-01120-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-022-01120-5
- Springer Nature America, Inc.